trending Market Intelligence /marketintelligence/en/news-insights/trending/6xejsl29b0o3zbaq25uupa2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Mast Therapeutics lays off staff

Brazil Pay TV Down Record Amount In 2019, With Losses Continuing In Q1'20

Impact of COVID 19 on US Video Entertainment Trends

Case Study: Transforming Sales Enablement Data at a Global Advertising and Media Firm

Key Credit Risk Factors When Assessing Banks In The Context Of COVID-19

Mast Therapeutics lays off staff

Mast Therapeutics Inc. laid off some of its employees as part of a cost-cutting measure.

The restructuring is meant to return focus to AIR001, a clinical-stage investigational drug for treating patients with heart failure as a result of preserved ejection fraction.

Mast Therapeutics is exploring opportunities to monetize its Vepoloxamer programs so it could advance AIR001 instead. Vepoloxamer itself is meant to be used in the sickle cell disease and heart failure.